Preliminary results on 225Ac-DOTATATE Targeted Alpha Therapy in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: First Clinical Experience on Safety and Efficacy

被引：0
|
作者：
Ballal, S. [1 ]
Yadav, M. P. [1 ]
Bal, C. [1 ]
机构：
[1] All India Inst Med Sci, New Delhi, India
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2019年 / 46卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-761
引用
收藏
页码：S288 / S288
页数：1
相关论文
共 50 条
  • [21] Efficiency and Safety of Targeted Alpha Therapy in Metastatic Neuroendocrine Tumors A Meta-analysis
    Lee, Dong Yun
    Kim, Yong-il
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (01) : e1 - e6
  • [22] Radiolabeling and preclinical evaluation of [225Ac]Ac-DOTA-JR11 for targeted alpha therapy of neuroendocrine tumors
    Handula, M.
    De Blois, E.
    Nonnekens, J.
    Denkova, A.
    Seimbille, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S32 - S32
  • [23] Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Sahoo, Ranjit Kumar
    Tripathi, Madhavi
    Seth, Amlesh
    Bal, Chandrasekhar
    THERANOSTICS, 2020, 10 (20): : 9364 - 9377
  • [24] Efficacy and Safety of 225Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, M.
    Ballal, S.
    Bal, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S420 - S420
  • [25] Efficacy and safety of 177Lu-DOTATATE targeted therapy in advanced/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis
    Ma, Jiao
    Hu, Xin
    Li, Lanying
    Rao, Zijuan
    Zhang, Chunyin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience
    Dureja, S.
    Sen, I
    Pant, V
    Thak, P.
    NEUROENDOCRINOLOGY, 2018, 106 : 244 - 244
  • [27] Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting
    Kalshetty, Ashwini
    Ramaswamy, Anant
    Ostwal, Vikas
    Basu, Sandip
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (12) : 1143 - 1149
  • [28] Phase 2 study of Lu-177-DOTATATE in combination with olaparib in patients with metastatic or inoperable GI neuroendocrine tumors - first results on safety and efficacy
    Lin, Frank
    Shamis, Inna
    Zou, Joy
    Carrasquillo, Jorge
    Turkbey, Baris
    Mena, Esther
    Lindenberg, Liza
    Chen, Clara
    Millo, Corina
    Herscovitch, Peter
    Pacak, Karel
    del Rivero, Jaydira
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [29] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Yeokyeong Shin
    Bo Hyun Moon
    Baek-Yeol Ryoo
    Heung-Moon Chang
    Kyu-pyo Kim
    Yong Sang Hong
    Tae Won Kim
    Jin-Sook Ryu
    Yong-il Kim
    Changhoon Yoo
    Targeted Oncology, 2024, 19 : 41 - 49
  • [30] Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea
    Shin, Yeokyeong
    Moon, Bo Hyun
    Ryoo, Baek-Yeol
    Chang, Heung-Moon
    Kim, Kyu-pyo
    Hong, Yong Sang
    Kim, Tae Won
    Ryu, Jin-Sook
    Kim, Yong-il
    Yoo, Changhoon
    TARGETED ONCOLOGY, 2024, 19 (01) : 41 - 49
12345